Drugs Containing Excipient (Inactive Ingredient) ACETYL TETRAPEPTIDE-3

Generic drugs containing ACETYL TETRAPEPTIDE-3 excipient

Company	Ingredient	NDC	Excipient
Consilii LLC	5% minoxidil hair growth oil	83299-017	ACETYL TETRAPEPTIDE-3

Acetyl Tetrapeptide-3 Market Dynamics and Financial Trajectory

Last updated: August 10, 2026

Acetyl Tetrapeptide-3 is a specialty cosmetic peptide used primarily in hair-density, scalp-care and anti-aging formulations. It is not an approved pharmaceutical active ingredient or a conventional pharmaceutical excipient. Its commercial value comes from inclusion in branded cosmetic active systems, especially peptide-and-botanical combinations marketed for hair appearance and scalp condition.

The ingredient has an attractive commercial profile: low use concentrations, compatibility with premium positioning, and strong fit with the expanding scalp-care and cosmetic hair-growth category. Its limitations are also clear. Public revenue data for Acetyl Tetrapeptide-3 alone are unavailable, clinical evidence is narrower than for pharmaceutical hair-loss products, and the ingredient competes with established actives such as minoxidil, caffeine, peptides, botanical extracts and newer cosmetic growth-factor technologies.

What is Acetyl Tetrapeptide-3 and how is it used?

Acetyl Tetrapeptide-3 is a synthetic acetylated peptide used in cosmetic formulations. It is commonly associated with scalp and hair products that claim to improve the appearance of hair density, strengthen the hair environment or support healthier-looking follicles.

The ingredient is usually not sold as a stand-alone consumer product. It is incorporated into finished formulations or supplied as part of a proprietary active blend. One of the best-known commercial systems associated with the ingredient is Capixyl, which combines Acetyl Tetrapeptide-3 with an extract of red clover, Trifolium pratense. Capixyl is marketed for scalp and hair-care applications by Lucas Meyer Cosmetics, a Clariant business.[1]

Typical applications include:

• Leave-on scalp serums
• Hair-density treatments
• Anti-hair-loss cosmetic products
• Shampoos and conditioners
• Eyebrow and eyelash products
• Anti-aging skin products
• Premium cosmeceutical formulations

The ingredient’s economic role is closer to a high-value cosmetic active than to a bulk excipient. It is purchased for marketing differentiation and claim support, not primarily for tablet manufacture, capsule filling or parenteral formulation.

Is Acetyl Tetrapeptide-3 a pharmaceutical excipient?

No. Acetyl Tetrapeptide-3 is principally a cosmetic ingredient and should not be treated as a pharmaceutical excipient without jurisdiction-specific regulatory support.

In the United States, cosmetic ingredients generally do not require premarket FDA approval, except for color additives. The manufacturer remains responsible for product safety and labeling under the Federal Food, Drug, and Cosmetic Act and the Modernization of Cosmetics Regulation Act of 2022.[2]

Acetyl Tetrapeptide-3 does not have the commercial profile of established pharmaceutical excipients such as microcrystalline cellulose, hypromellose, polyethylene glycol or polysorbates. It is not commonly identified as an inactive ingredient in approved drug products, and it does not have a meaningful Orange Book position.

Regulatory issue	Status for Acetyl Tetrapeptide-3
Primary commercial category	Cosmetic active ingredient
U.S. drug approval	No identified approved drug-active status
U.S. Orange Book listing	No meaningful listing identified
Pharmaceutical excipient role	Not established as a mainstream excipient
Cosmetic INCI use	Yes, subject to market and formulation compliance
EU cosmetics framework	Governed principally under Regulation (EC) No. 1223/2009
FDA premarket approval	Generally not required for cosmetic ingredients
Drug-like hair-loss claim risk	High if claims imply treatment or regrowth of disease

A product marketed as treating androgenetic alopecia, reversing hair loss or stimulating follicular regrowth may move toward drug regulation depending on its claims, formulation and jurisdiction. Cosmetic products generally must limit claims to appearance, conditioning, strengthening or similar functions unless the manufacturer has drug authorization.

How large is the Acetyl Tetrapeptide-3 market?

No reliable public source reports a standalone global market size for Acetyl Tetrapeptide-3. The commercial market is fragmented across ingredient sales, proprietary blends, contract manufacturing and finished cosmetic products. Public company filings do not generally break out revenue by peptide, active system or individual ingredient.

The most defensible market assessment uses downstream categories as proxies:

1. Premium scalp-care products
2. Hair-density and hair-thinning cosmetics
3. Cosmetic peptides
4. Cosmeceuticals
5. Anti-aging skin-care products

The broader beauty and personal-care market is large, but Acetyl Tetrapeptide-3 captures only a small portion of it. Its addressable market is defined by premium formulations that can support peptide-based claims and tolerate higher ingredient costs.

Market demand is supported by five factors:

• Rising consumer concern about hair thinning
• Increased use of leave-on scalp products
• Growth of direct-to-consumer beauty brands
• Premiumization of cosmetic treatments
• Consumer preference for non-drug and non-invasive options

Demand is constrained by limited consumer awareness of the individual peptide. Most purchasing decisions are made at the product or brand level. The ingredient therefore creates value indirectly through the claims, formulation story and clinical or instrumental data attached to the finished product.

What is driving demand for Acetyl Tetrapeptide-3?

Scalp care is expanding faster than traditional shampoo

Scalp care has moved from a cleansing category toward treatment-style routines. Serums, tonics, masks and pre-wash products allow brands to use higher-value actives and generate repeat purchases. Acetyl Tetrapeptide-3 fits this format because it can be positioned in leave-on products with premium pricing.

Hair-thinning claims are commercially attractive

Hair loss has high consumer salience, but pharmaceutical treatment carries concerns about side effects, long-term use and medical consultation. Cosmetic brands use peptides, botanical extracts, vitamins and caffeine to occupy the adjacent “hair wellness” segment.

This creates a large claims opportunity but also a regulatory boundary. Statements such as “supports stronger-looking hair” are generally lower risk than “regrows hair” or “treats alopecia.” Enforcement and classification depend on the complete product presentation, not only the ingredient name.

Proprietary blends increase pricing power

Acetyl Tetrapeptide-3 is more commercially defensible when sold in a branded system with:

• A defined peptide concentration
• A botanical co-active
• Stability and compatibility data
• In vitro or ex vivo support
• Human-use testing
• Finished-product claim substantiation

A branded blend can command a premium over an unbranded peptide because formulation customers are buying technical support, documentation and marketing rights as well as raw material.

Peptides support premium cosmetic positioning

Cosmetic peptides are associated with high-performance skin and hair care. They can be used at low concentrations, which reduces the amount of active required per unit of finished product. The cost of the peptide may still be material, but the total formula cost can remain manageable when the product is sold as a serum or treatment.

How does Acetyl Tetrapeptide-3 compare with competing hair-care actives?

Acetyl Tetrapeptide-3 competes across different evidence and pricing tiers. It does not compete only with other peptides.

Active category	Examples	Primary positioning	Evidence and regulatory profile	Commercial threat
Pharmaceutical hair-loss active	Minoxidil	Hair-loss treatment and regrowth	Drug-regulated; stronger therapeutic recognition	High
Cosmetic stimulant	Caffeine	Scalp stimulation and hair appearance	Broad cosmetic use; lower cost	High
Botanical active	Red clover, saw palmetto, rosemary	Natural hair and scalp care	Variable evidence; strong consumer appeal	High
Cosmetic peptide	Acetyl Tetrapeptide-3, copper peptides	Hair density, scalp support, anti-aging	Premium cosmetic positioning	Direct
Growth-factor technology	Biomimetic peptides, conditioned media	Advanced cosmetic regeneration claims	High technical and regulatory scrutiny	Medium
Nutraceutical active	Biotin, zinc, amino acids	Beauty-from-within	Oral supplement category; commoditized	Medium
Mechanical or device-based product	Laser devices, microneedling	Hair-density support	Device and procedure claims	Medium

Minoxidil has a stronger evidence and regulatory position for androgenetic alopecia, but it also carries drug-labeling requirements and a more restricted claims environment. Acetyl Tetrapeptide-3 has greater flexibility for cosmetic branding, but its efficacy claims must remain within cosmetic boundaries.

Caffeine and botanical extracts create substantial price pressure because they are widely available and often cheaper. Peptides retain an advantage when brands target consumers willing to pay for concentrated serums and clinically presented formulations.

What formulation formats are protected or commercially differentiated?

There is no single formulation architecture associated exclusively with Acetyl Tetrapeptide-3. Commercial differentiation usually comes from the combination of peptide, botanical extract, delivery system and finished-product claims.

Common formulation approaches include:

• Aqueous scalp serums
• Hydroalcoholic tonics
• Emulsion-based scalp treatments
• Shampoo and conditioner systems
• Liposomal or encapsulated peptide systems
• Peptide-botanical blends
• Multi-active anti-aging products

The technical issues are typical of peptide formulation:

• pH control
• Hydrolysis risk
• Preservative compatibility
• Interaction with surfactants
• Adsorption to packaging
• Heat and light sensitivity
• Compatibility with botanical extracts
• Batch-to-batch assay control

The competitive advantage often lies in the supplier’s formulation package rather than the molecule itself. Stability data, recommended use levels, analytical methods and finished-product testing can reduce switching by customers.

What patent protection covers Acetyl Tetrapeptide-3?

The strongest commercial protection is likely to arise from proprietary blends, manufacturing processes, formulations and use claims rather than broad ownership of the peptide concept.

Potential IP categories include:

1. Composition claims covering the peptide sequence or acetylated structure.
2. Manufacturing claims covering synthesis, purification or yield improvement.
3. Formulation claims covering the peptide with red clover or other actives.
4. Delivery claims covering encapsulation or controlled release.
5. Cosmetic use claims directed to hair density, scalp condition or follicular support.
6. Trademark and trade-secret protection covering branded active systems.

Patent strength is limited when claims are narrow, obvious combinations are easy to design around, or the underlying peptide sequence is already disclosed in earlier literature. A branded active can remain commercially valuable even after core composition patents weaken if the supplier controls clinical data, customer relationships, formulation know-how and trademark rights.

A serious freedom-to-operate review should search:

• The exact peptide name and sequence
• Acetylated tetrapeptide structures
• Capixyl and related trademarks
• Red clover-peptide combinations
• Hair-growth and follicle-support method claims
• Encapsulation and delivery systems
• Supplier-specific patent families
• National-phase filings in the United States, Europe, China, Japan and South Korea

Public patent information does not establish a single, clearly defined global exclusivity period for all Acetyl Tetrapeptide-3 commercial uses. Patent rights must be assessed family by family and claim by claim.

When does Acetyl Tetrapeptide-3 lose exclusivity?

There is no FDA drug exclusivity date or Orange Book patent expiration date governing Acetyl Tetrapeptide-3 as a cosmetic ingredient.

The relevant exclusivity risks are commercial and IP-based:

• Composition patents may expire approximately 20 years from the earliest effective nonprovisional filing date, subject to jurisdictional adjustments.
• Formulation and use patents may expire later than composition patents if filed after the ingredient’s initial development.
• Trade-secret protection for manufacturing and formulation methods can continue indefinitely while secrecy is maintained.
• Trademark protection can continue through renewal, provided the mark remains in use and meets local requirements.
• Cosmetic ingredient suppliers may lose practical exclusivity before formal patent expiry if alternative manufacturers can synthesize the same peptide.

The absence of drug exclusivity makes generic entry less structured than in pharmaceuticals. A competing supplier does not need to file an abbreviated new drug application merely to sell a cosmetic ingredient. Its primary obligations are product safety, quality, labeling and compliance with the destination market.

Are there Paragraph IV challenges or generic launch risks?

No conventional Paragraph IV pathway applies because Acetyl Tetrapeptide-3 is not an FDA-approved small-molecule drug with Orange Book-listed patents.

The relevant competitive event is supplier substitution rather than generic drug launch. Entry can occur through:

• Direct synthesis of the peptide
• Licensing of a manufacturing process
• Sale of a chemically equivalent raw material
• Development of a competing blend
• Replacement with a lower-cost peptide
• Use of a botanical or caffeine-based alternative

Brand owners face a different risk. A finished cosmetic product can be reformulated without changing its market category, provided the revised product remains safe, stable and compliant with its claims. That creates switching pressure on ingredient suppliers.

What companies influence the commercial landscape?

The commercial ecosystem has four layers.

Ingredient and active-system suppliers

Lucas Meyer Cosmetics, part of Clariant, is associated with Capixyl and represents the most visible branded commercial platform linked to Acetyl Tetrapeptide-3.[1] Other specialty peptide suppliers may offer equivalent or competing materials, although public disclosure of individual sales volumes is limited.

Contract manufacturers

Private-label and contract manufacturers translate the ingredient into scalp serums, shampoos, masks and treatment kits. Their purchasing power can pressure supplier pricing, particularly when formulas are standardized.

Finished-product brands

Dermocosmetic, premium hair-care and direct-to-consumer brands create end-market demand. Their value depends on claims, consumer reviews, clinical presentation and distribution rather than ingredient identity alone.

Competing active suppliers

Suppliers of caffeine, plant extracts, copper peptides, biomimetic peptides and delivery technologies compete for the same formulation budget. The buyer often evaluates a complete claim package rather than one molecule.

What is the financial trajectory for Acetyl Tetrapeptide-3?

The likely financial trajectory is positive but modest at the ingredient level and more attractive at the active-system and finished-product levels.

Early stage: technical adoption

Initial value creation comes from supplier qualification, formulation trials and pilot launches. Revenue is project-based and depends on a small number of cosmetic customers. Volumes are limited, but gross margins can be high because the material is sold as a specialty active.

Growth stage: branded scalp-care expansion

As more brands launch hair-density serums, demand shifts from laboratory sampling to recurring commercial orders. The supplier can improve economics through:

• Larger batch production
• Standardized quality specifications
• Distributor networks
• Regional regulatory dossiers
• Brand licensing
• Clinical substantiation packages

Mature stage: price competition and substitution

As the ingredient becomes familiar, unbranded peptide alternatives and competing blends place pressure on pricing. The supplier must defend its position through data, formulation support, trademark strength and customer integration.

A reasonable commercial model is:

Revenue layer	Margin potential	Main value driver
Raw peptide supply	Moderate to high	Purity, scale and manufacturing efficiency
Branded active blend	High	Data package, trademark and formulation support
Licensed technology	High but uneven	Contract terms and exclusivity
Finished cosmetic product	Variable to high	Brand, claims and distribution
Pharmaceutical development	Low probability based on current positioning	Regulatory and clinical investment

Public financial statements from diversified suppliers do not isolate Acetyl Tetrapeptide-3 revenue. The ingredient should therefore be valued through customer adoption, repeat order rates, active-system pricing, production scale and exposure to scalp-care growth rather than through a standalone market-capitalization or revenue multiple.

What FDA and international regulatory issues affect commercial growth?

In the United States, a cosmetic product must be safe and properly labeled. MoCRA expanded facility registration, product listing, adverse-event reporting and safety substantiation obligations for many cosmetic businesses.[2]

In the European Union, cosmetic products must comply with Regulation (EC) No. 1223/2009, including a responsible person, product information file, safety assessment and compliant claims.[3] Ingredient status and nomenclature can be checked through the European Commission’s CosIng database, but inclusion in CosIng does not itself constitute product approval or efficacy validation.[4]

The principal regulatory risk is claim escalation. A product using Acetyl Tetrapeptide-3 can remain a cosmetic when it conditions hair or improves appearance. Claims that the product treats alopecia, reverses follicular miniaturization or regrows hair can create drug or medicinal-product exposure.

How strong is the commercial position of Acetyl Tetrapeptide-3?

The commercial position is moderately strong in premium cosmetic hair care but weak as a pharmaceutical asset.

Strengths include:

• Low-dose specialty-active economics
• Fit with scalp-care growth
• Compatibility with premium serum formats
• Ability to combine with botanical ingredients
• Use in finished products without drug approval when claims remain cosmetic
• Potential supplier lock-in through data and formulation support

Weaknesses include:

• No established pharmaceutical exclusivity
• Limited public standalone market data
• Competition from cheaper actives
• Difficulty proving clinical superiority
• Dependence on consumer-facing claims
• Potential substitution by other peptides or botanical systems
• Limited visibility into supplier manufacturing economics

The strongest investment thesis is not ownership of the peptide alone. It is control of a differentiated active platform with validated formulations, branded ingredients, clinical support and distribution into premium scalp-care brands.

Key Takeaways

• Acetyl Tetrapeptide-3 is primarily a cosmetic active, not a mainstream pharmaceutical excipient.
• Its best-known commercial association is Capixyl, a peptide-and-red-clover active system linked to Lucas Meyer Cosmetics.
• No standalone public revenue figure or FDA drug exclusivity date is established.
• Market growth is tied to premium scalp care, hair-density serums and non-drug hair-loss positioning.
• The main competitors are minoxidil, caffeine, botanical extracts, copper peptides and newer biomimetic peptide systems.
• Commercial protection depends on formulation know-how, clinical data, trademarks, supplier relationships and manufacturing controls.
• Paragraph IV challenges and Orange Book litigation are not the relevant risk framework.
• Generic entry is more likely to occur through cosmetic ingredient substitution and competing active blends.
• Financial upside is greater for branded active systems and finished products than for undifferentiated peptide supply.
• Regulatory exposure increases sharply when cosmetic claims imply treatment or regrowth of hair loss.

FAQs

Is Acetyl Tetrapeptide-3 approved by the FDA for hair loss?

No FDA drug approval for Acetyl Tetrapeptide-3 as a hair-loss treatment is established. It is used in cosmetic products subject to applicable safety, labeling and claim requirements.

Can Acetyl Tetrapeptide-3 be used in a pharmaceutical formulation?

It could theoretically be evaluated as a formulation component, but it is not an established mainstream pharmaceutical excipient. Its current commercial use is primarily cosmetic.

What is the typical concentration of Acetyl Tetrapeptide-3 in cosmetics?

Commercial use levels depend on the supplier, active blend and finished-product claims. Branded systems may be dosed according to the supplier’s recommended blend concentration rather than the concentration of the isolated peptide.

Does Acetyl Tetrapeptide-3 regrow hair?

Cosmetic products containing the peptide may claim improved hair appearance, density or scalp condition. Drug-like regrowth claims require a higher level of regulatory and clinical support than ordinary cosmetic claims.

Who manufactures Acetyl Tetrapeptide-3?

The ingredient is available through specialty cosmetic-ingredient suppliers and branded active-system manufacturers. Lucas Meyer Cosmetics, a Clariant business, is associated with Capixyl, one of the best-known commercial systems containing Acetyl Tetrapeptide-3.

References

1. Clariant. (n.d.). Capixyl: Hair care active ingredient. Lucas Meyer Cosmetics.
2. U.S. Food and Drug Administration. (2023). Modernization of Cosmetics Regulation Act of 2022.
3. European Parliament and Council of the European Union. (2009). Regulation (EC) No. 1223/2009 on cosmetic products.
4. European Commission. (n.d.). CosIng: Cosmetic ingredients database.
5. Cosmetics Europe. (2024). Cosmetics and personal care industry market information.